Cite
HARVARD Citation
Baik, C. et al. (2021). A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. Cancer treatment and research communications. p. . [Online].